Despite the potential value of new blood tests promoters say can identify Alzheimer’s disease long before symptoms arise, these tests raise many important issues that patients and their physicians should carefully consider before requesting or administering them. Because of those concerns, medical thought leaders are offering important guidance about how their colleagues should talk to their patients about the tests [...]
The idea that a simple blood can diagnose Alzheimer’s disease is getting an enormous amount of attention. And someday, these tests may have important benefits. But before you run to your doctor demanding a blood draw, keep in mind that this test has important limitations. Much of the buzz is over new research by Sebastian Palmqvist (paywall) of Lund University [...]
Too often, physicians are reluctant to give patients a diagnosis of dementia, even when cognitive testing shows memory loss or other symptoms. And when doctors do provide a candid diagnosis, they may send their patients and their families home without any guidance for what to do next. No practical advice. No sense of hope. And too often, not even any [...]
Last year, Medicare decided it would routinely pay for sophisticated imaging tests for Alzheimer’s disease called amyloid-PET (positron emission tomography) scans. The move will make it easier for people with early-stage memory loss to get tested and potentially become eligible for a class of new drugs that aim to slow the progression of Alzheimer’s. However, many neuroscientists and imaging experts [...]
The National Institutes of Health’s Institute of Aging has dropped its name from a controversial joint project with Alzheimer’s Association to revise clinical research standards, which it calls criteria, for determining who has Alzheimer’s disease. The relationship was unusual. NIH rarely sponsors projects to develop such standards, and almost never partners with advocacy groups. Typically, such guidance is written by expert panels organized [...]
The National Institute on Aging and the Alzheimer’s Association have proposed revised clinical guidelines that would designate seven major stages of the brain disease. The first two would be for people who have no symptoms but may be at higher risk for Alzheimer’s. These technical guidelines, which would update a 2018 version, could have enormous, and conflicting, implications for drug [...]
Living with memory loss and other cognitive limitations is hard. But when you can’t remember or can’t process information well enough to make important decisions, and you have no one by your side to support you, life can be extra tough. Researchers at the University of California San Francisco ((UCSF) estimate that about 4.3 million older adults with cognitive impairment [...]
The Food and Drug Administration (FDA) has granted final approval to the anti-Alzheimer’s drug lecanamab, marked as Leqembi by drugmakers Eisai and Biogen. Here is what you need to know: What does it do? In a formal phase 3 trial, Leqembi was shown to slow the progression of memory loss and cognitive impairment in patients with early-stage Alzheimer’s disease by [...]
Enormous attention is being given to controversial drugs aimed at slowing the progression of early-stage Alzheimer’s disease. Yet, a very different set of clinical innovations holds the promise of helping far more people living with dementia and their families in more immediate—and perhaps more effective—ways. These care delivery models are aimed at breaking down the often-impenetrable barriers between health care [...]
The drug industry and its supporters are blasting the Centers for Medicare and Medicaid Services (CMS) for proposing to limit Medicare payments for the new anti-Alzheimer’s drug lecanemab to patients who participate in a trial or a special registry aimed at tracking their experience with the drug. CMS says the record-keeping will help provide important, real-world information about the benefits [...]